Average Co-Inventor Count = 3.32
ph-index = 5
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. The United States of America, As Represented by the Secretary, Department of Health and Human Services (12 from 3,539 patents)
2. Amgen Inc. (3 from 1,975 patents)
3. The United States of America As Represented by the Department of Health (3 from 1,217 patents)
4. Other (1 from 832,880 patents)
5. The United States of America, Represented by the Secretary, U.S. Department of Commerce (0 patent)
16 patents:
1. 11434268 - Vascular endothelial growth factor antagonists
2. 10035833 - Vascular endothelial growth factor antagonists and methods of making
3. 9550818 - Methods for use of vascular endothelial growth factor antagonists
4. 8754081 - Compositions and methods for inhibition of hepatocyte growth factor receptor c-Met signaling
5. 8617831 - Methods for diagnosing and monitoring the progression of cancer by measuring soluble c-Met ectodomain
6. 8569360 - Compositions and methods for inhibition of hepatocyte growth factor receptor c-Met signaling
7. 8304199 - Methods for diagnosing and monitoring the progression of cancer by measuring soluble c-Met ectodomain
8. 7964365 - Methods for diagnosing and monitoring the progression of cancer
9. 7871981 - Inhibition of cell motility, angiogenesis, and metastasis
10. 7605127 - Truncated hepatocyte growth factor variant protein HGF/NK2
11. 7132392 - Inhibition of cell motility and angiogenesis by inhibitors of Grb2-SH2-domain
12. 6566098 - DNA encoding truncated hepatocyte growth factor variants
13. 6326466 - Double-stranded RNA dependent protein kinase derived peptides to promote proliferation of cells and tissues in a controlled manner
14. 5648273 - Hepatic growth factor receptor is the MET proto-oncogene
15. 5578566 - KGF receptor-derived antagonists of KGF binding